US 12,268,797 B2
Non-cultured, partially digested, cryopreserved cartilage product
Dana Sue Yoo, Falls Church, VA (US); Jin-Qiang Kuang, Woodstock, VA (US); Jaime Paden, Columbia, MD (US); Scott A. Maxson, Columbia, MD (US); Alla Danilkovitch, Columbia, MD (US); Erasmo Lopez, Somerville, NJ (US); and Samson Tom, Basking Ridge, NJ (US)
Assigned to OSIRIS THERAPEUTICS, INC., Columbia, MD (US)
Filed by OSIRIS THERAPEUTICS, INC., Columbia, MD (US)
Filed on Feb. 25, 2022, as Appl. No. 17/681,064.
Application 17/681,064 is a continuation of application No. 14/485,210, filed on Sep. 12, 2014, granted, now 11,406,735.
Application 14/485,210 is a continuation of application No. 13/939,991, filed on Jul. 11, 2013, abandoned.
Claims priority of provisional application 61/670,434, filed on Jul. 11, 2012.
Claims priority of provisional application 61/670,444, filed on Jul. 11, 2012.
Claims priority of provisional application 61/670,424, filed on Jul. 11, 2012.
Prior Publication US 2022/0184277 A1, Jun. 16, 2022
This patent is subject to a terminal disclaimer.
Int. Cl. A61L 27/36 (2006.01); A61K 35/32 (2015.01); A61K 38/01 (2006.01); A61L 27/24 (2006.01); A61L 27/38 (2006.01); A61L 27/50 (2006.01); A61L 27/54 (2006.01); A61L 27/56 (2006.01)
CPC A61L 27/3612 (2013.01) [A61K 35/32 (2013.01); A61K 38/014 (2013.01); A61L 27/24 (2013.01); A61L 27/3608 (2013.01); A61L 27/3654 (2013.01); A61L 27/3683 (2013.01); A61L 27/3687 (2013.01); A61L 27/3691 (2013.01); A61L 27/3817 (2013.01); A61L 27/3852 (2013.01); A61L 27/50 (2013.01); A61L 27/54 (2013.01); A61L 27/56 (2013.01); A61L 2300/414 (2013.01); A61L 2300/64 (2013.01); A61L 2430/06 (2013.01)] 26 Claims
OG exemplary drawing
 
1. A flexible cryopreserved partially digested cartilage material comprising non-cultured cartilage isolated from a subject, wherein:
the material comprises an extracellular matrix, growth factors, and chondrocytes,
wherein the extracellular matrix, growth factors, and chondrocytes were embedded in the material when it was isolated from the subject, and
wherein at least 70% of the chondrocytes are viable; and
the material has a first circular-shaped surface, an opposing second circular-shaped surface, and a thickness of 0.2 millimeters (mm) to 2 mm,
wherein the first circular-shaped surface has an array of cavities capable of facilitating migration of the chondrocytes,
wherein, after cryopreserving, the material retains the structural and functional properties of natural cartilage,
wherein digestion of the material is limited to an amount that preserves the viability of the chondrocytes and/or the structural and functional properties of natural cartilage, and
wherein digestion is performed in a manner that retains interaction between the extracellular matrix and the chondrocytes.